The effects of rifampicin and fluoroquinolones on tubercle bacilli within human macrophages

International Journal of Antimicrobial Agents

Volumn 23, Issue 1, 2004, Pages 84-87

  Duman, Necdet ^a   Çevikbaş, Adile ^a   Johansson, Candan ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b MALTEPE UNIVERSITY   (Turkey)

Author keywords

Fluoroquinolones; Human macrophage; M. tuberculosis; Rifampicin

Indexed keywords

AGAR; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EXPERIMENTAL INFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0347090626     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.05.017     Document Type: Article

References (39)

1. Chan J., Fan X., Hunter W.S., Brennan J.P., Bloom R.B. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59:1991;1755-1761.
2. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72:1-6.
3. Berning S.E. The role of fluoroquinolones in tuberculosis today. Drugs. 61:2001;9-18.
4. Alastair J.J., Wood M.D. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329:1993;784-791.
5. Singla R., Gupta S., Gupta R., Arora V.K. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients preliminary results. Int. J. Tuberc. Lung Dis. 5:2001;559-563.
6. Rastogi N., Labrousse V., Goh K.S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33:1996;167-175.
7. Salyers AA, Whitt DD. Tuberculosis. In: Bacterial pathogenesis a molecular approach. Washington; 1994. p. 304-27.
8. 2 production: reversal by gamma interferon. Infect. Immun. 57:1989;864-869.
9. Kennedy N., Fox R., Kisyombe M.G.et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am. Rev. Respir. Dis. 148:1993;1547-1551.
10. Gorzynski A.E., Gutman I.S., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob. Agents Chemother. 33:1989;591-592.
11. Truffot-Pernoy C.I.J.B., Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle. 72:1991;181-186.
12. Inderlied B.C. Antimycobacterial susceptibility testing: present practices and future trends. Eur. J. Clin. Microbiol. Infect. Dis. 13:1994;980-993.
13. Berlin W.G.O., Young S.L., Bruckner A.D. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 19:1987;611-615.
14. Crowle A.J., Sbarbaro J.A., Judson F.N., Douvas G.S., May M.H. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages. Am. Rev. Respir. Dis. 130:1984;839-844.
15. Crowle A.J., Sbarbaro J.A., May M. Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. Tubercle. 69:1988;15-25.
16. Crowle A.J., Sbarbaro J.A., Judson F.N., May M.H. The effect of ethambutol on tubercle bacilli within cultured human macrophages. Am. Rev. Respir. Dis. 132:1985;742-745.
17. Wallace J.R., Nash R.D., Steele C.L., Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J. Clin. Microbiol. 24:1986;976-978.
18. Crowle A.J., Elkins N., May M.H. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am. Rev. Respir. Dis. 137:1988;1141-1146.
19. Hawkins EJ, Wallace JR, Brown AB. Antibacterial susceptibility tests. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Mycobacteria in manual of clinical microbiology, 5th ed. Washington; 1991. p. 1138-50.
20. Cohen Y., Perronne C., Truffot-Pernot C., Grosset J., Vilde J.L., Pocidalo J.J. Activities of win-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob. Agents Chemother. 36:1992;2104-2107.
21. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Pocidalo J.J., Vilde J.L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob. Agents Chemother. 34:1990;1508-1511.
22. Cooksey C.R., Crawford T.J., Jacobs R.W., Shinnick M.T. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1993;1348-1352.
23. Kasahara K., Toble T., Tomita M.et al. Selective expression of monocyte chemotactic and activating factor/monocyte chemoattractant protein 1 in human blood monocytes by Mycobacterium tuberculosis. J. Infect. Dis. 170:1994;1238-1247.
24. Mor N.H. MIC and MBCs of clarithromycin against Mycobacterium avium with human macrophages. Antimicrob. Agents Chemother. 37:1993;111-114.
25. Bermudez L.E., Wu M., Petrofsky M., Young L.S. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect. Immun. 60:1992;4245-4252.
26. Gascon P., Sathe S., Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Amer. J. Med. 94:1993;41-48.
27. Crowle A.J., Poche P. Inhibition by normal human serum of Mycobacterium avium multiplication in cultured human macrophages. Infect. Immun. 57:1989;1332-1335.
28. Nakamura S., Minami A., Nakata K.et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob. Agents Chemother. 33:1989;1167-1173.
29. Hoffner S.E., Gezelius L., Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 40:1997;885-888.
30. Tomioka H., Sato K., Kajitani H., Akkari T., Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterim avium complex. Antimicrob. Agents Chemother. 44:2000;283-286.
31. Chadwick M., Nicholson G., Gaya H. Path FRC. Brief report: Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models. Amer. J. Med. 87:1989;35S-36S.
32. Lalande V., Truffot-Pernot C., Paccaly-Moulin A., Grosset J., Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in 7 mice. Antimicrob. Agents Chemother. 37:1993;407-413.
33. Piersimoni C., Morbiducci V., Bornigia S., De Sio G., Scalise G. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 146:1992;1445-1447.
34. Wise R. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. Am. J. Med. 91:1991;67S-70S.
35. Skinner P.S., Furney S.K., Kleinert D.A., Orme I.M. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1995;750-753.
36. Alangaden G.J., Lerner S.A. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25:1997;1213-1221.
37. Nakamura S., Kurobe N., Ohue T., Hashimoto M., Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob. Agents Chemother. 34:1990;89-93.
38. Vachera S., pellgrina J.L., Leblancb F., Fourchea J., Maugeina J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J. Antimicrob. Chemother. 44:1999;647-652.
39. Jacobs M.R. Activity of quinolones against mycobacteria. Drugs. 58:1999;19-22.